$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

$pbyi Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000143774922011142 Filed on May 05, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$45.74M	$98.17M
YoY Change	-53.41%	91.67%
Cost Of Revenue	$10.84M	$29.56M
YoY Change	-63.31%	225.52%
Gross Profit	$34.89M	$68.61M
YoY Change	-49.15%	62.82%
Gross Profit Margin	76.29%	69.89%
Selling, General & Admin	$20.40M	$28.24M
YoY Change	-27.75%	-8.72%
% of Gross Profit	58.47%	41.16%
Research & Development	$15.24M	$20.23M
YoY Change	-24.67%	-20.53%
% of Gross Profit	43.67%	29.48%
Depreciation & Amortization	$200.0K	$200.0K
YoY Change	0.0%	0.0%
% of Gross Profit	0.57%	0.29%
Operating Expenses	$35.64M	$48.47M
YoY Change	-26.47%	-25.97%
Operating Profit	-$747.0K	$20.15M
YoY Change	-103.71%	-186.36%
Interest Expense	$2.664M	$3.450M
YoY Change	-22.78%	12.45%
% of Operating Profit		17.12%
Other Income/Expense, Net	-$2.619M	-$3.580M
YoY Change	-26.84%	33.48%
Pretax Income	-$3.366M	$16.57M
YoY Change	-120.32%	-197.83%
Income Tax	$37.00K	$38.00K
% Of Pretax Income		0.23%
Net Earnings	-$3.403M	$16.53M
YoY Change	-120.59%	-197.61%
Net Earnings / Revenue	-7.44%	16.84%
Basic Earnings Per Share	-$0.08	$0.41
Diluted Earnings Per Share	-$0.08	$0.40
COMMON SHARES
Basic Shares Outstanding	42.21M	40.26M
Diluted Shares Outstanding	42.21M	40.90M

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$73.91M	$109.1M
YoY Change	-32.26%	8.45%
Cash & Equivalents	$63.91M	$95.70M
Short-Term Investments	$9.994M	$13.40M
Other Short-Term Assets	$631.0K	$373.0K
YoY Change	69.17%	-98.4%
Inventory	$7.277M	$7.700M
Prepaid Expenses	$8.716M
Receivables	$27.04M	$21.80M
Other Receivables	$5.138M	$4.400M
Total Short-Term Assets	$117.6M	$163.8M
YoY Change	-28.22%	3.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.591M	$2.283M
YoY Change	-30.31%	-26.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.030M	$4.600M
YoY Change	-12.39%	-26.98%
Total Long-Term Assets	$83.12M	$94.86M
YoY Change	-12.38%	42.0%
TOTAL ASSETS
Total Short-Term Assets	$117.6M	$163.8M
Total Long-Term Assets	$83.12M	$94.86M
Total Assets	$200.7M	$258.7M
YoY Change	-22.41%	14.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.412M	$10.65M
YoY Change	-30.43%	-38.42%
Accrued Expenses	$61.84M	$79.28M
YoY Change	-22.01%	14.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$22.86M
YoY Change
Total Short-Term Liabilities	$74.79M	$140.4M
YoY Change	-46.73%	55.19%
LONG-TERM LIABILITIES
Long-Term Debt	$97.38M	$76.35M
YoY Change	27.55%	-20.31%
Other Long-Term Liabilities	$21.37M	$25.50M
YoY Change	-16.2%	-14.72%
Total Long-Term Liabilities	$97.38M	$76.35M
YoY Change	27.55%	-39.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$74.79M	$140.4M
Total Long-Term Liabilities	$97.38M	$76.35M
Total Liabilities	$193.5M	$242.2M
YoY Change	-20.1%	12.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.370B
YoY Change
Common Stock	$1.377B	$1.338B
YoY Change	2.97%	2.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.145M	$16.34M
YoY Change
Total Liabilities & Shareholders Equity	$200.7M	$258.7M
YoY Change	-22.43%	14.71%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$3.403M	$16.53M
YoY Change	-120.59%	-197.61%
Depreciation, Depletion And Amortization	$200.0K	$200.0K
YoY Change	0.0%	0.0%
Cash From Operating Activities	-$26.90M	$15.66M
YoY Change	-271.76%	-235.71%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$8.982M	-$5.300M
YoY Change	-269.47%	-115.42%
Cash From Investing Activities	$8.982M	-$5.301M
YoY Change	-269.44%	-115.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$9.845M	$0.00
YoY Change
NET CHANGE
Cash From Operating Activities	-$26.90M	$15.66M
Cash From Investing Activities	$8.982M	-$5.301M
Cash From Financing Activities	$9.845M	$0.00
Net Change In Cash	-$8.068M	$10.36M
YoY Change	-177.88%	-54.64%
FREE CASH FLOW
Cash From Operating Activities	-$26.90M	$15.66M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	pbyi	Number Of Subsidiaries NumberOfSubsidiaries	1	pure
CY2021	pbyi	Number Of Subsidiaries NumberOfSubsidiaries	2	pure
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	8000000.0	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	8000000.0	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8000000.0	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	8000000.0	USD
CY2022Q1	pbyi	Finitelived Intangible Asset Expected Amortization Year Six FinitelivedIntangibleAssetExpectedAmortizationYearSix	8000000.0	USD
CY2022Q1	pbyi	Finitelived Intangible Asset Expected Amortization Year Seven FinitelivedIntangibleAssetExpectedAmortizationYearSeven	8000000.0	USD
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44973141
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2022Q1	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	2000000.0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44949360
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44949360
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41175507
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41175507
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	200000	USD
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63913000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63131000	USD
CY2022Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	9994000	USD
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	18975000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27039000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	32526000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	7277000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	7109000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8716000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8984000	USD
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	8850000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	631000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	447000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	117570000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	140022000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13373000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14017000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1591000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1756000	USD
CY2022Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	64121000	USD
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	66125000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	3450000	USD
CY2022Q1	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-18000	USD
CY2021Q1	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-185000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	50000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	42000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2619000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3580000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3311000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3311000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	719000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1354000	USD
CY2022Q1	us-gaap	Assets Assets	200685000	USD
CY2021Q4	us-gaap	Assets Assets	226585000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	7412000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11174000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	61837000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	92575000	USD
CY2022Q1	pbyi	Post Marketing Commitment Liability Current PostMarketingCommitmentLiabilityCurrent	1842000	USD
CY2021Q4	pbyi	Post Marketing Commitment Liability Current PostMarketingCommitmentLiabilityCurrent	2263000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3698000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3574000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	74789000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	109586000	USD
CY2022Q1	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	756000	USD
CY2021Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	915000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15012000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15975000	USD
CY2022Q1	pbyi	Postmarketing Commitment Liability Noncurrent PostmarketingCommitmentLiabilityNoncurrent	5602000	USD
CY2021Q4	pbyi	Postmarketing Commitment Liability Noncurrent PostmarketingCommitmentLiabilityNoncurrent	5463000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97381000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97092000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	193540000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	229031000	USD
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1377302000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1364309000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1370160000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1366757000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	7145000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2446000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	200685000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	226585000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45736000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	98169000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10844000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	29557000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20402000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28238000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15237000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20228000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	46483000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	78023000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-747000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	20146000	USD
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	13000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	13000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	2664000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3366000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	16566000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	37000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	38000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3403000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	16528000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.41
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.40
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42207709
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40260864
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42207709
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40894868
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3403000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	16528000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3402000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	16528000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2446000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3148000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	USD
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9845000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3403000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	7145000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-5951000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5860000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	16528000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	16437000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3403000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	16528000	USD
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2262000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2951000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3148000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5860000	USD
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1000	USD
CY2021Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5487000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	615000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	168000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4291000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-903000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-88000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	184000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-3268000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3762000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1422000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-30897000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-6556000	USD
CY2022Q1	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-282000	USD
CY2021Q1	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-150000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26895000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	15661000	USD
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	-0	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	10696000	USD
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	8982000	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	5395000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8982000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5301000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10000000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	155000	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9845000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8068000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10360000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	75292000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	97454000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	67224000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	107814000	USD
CY2022Q1	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2021Q1	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	20000000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	2375000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	2250000	USD
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2021Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	12000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3400000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26900000	USD
CY2022Q1	pbyi	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	73900000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Use of Estimates: </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The preparation of consolidated financial statements in conformity with US GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of revenues and expenses for the period presented. Accordingly, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products.</p>
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8726907000
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8818465000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3403000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	16528000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42208000
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40261000
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2021Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	634000
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42208000
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40895000
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.41
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.40
CY2022Q1	pbyi	Sublease Agreement Potential Milestone Payments SubleaseAgreementPotentialMilestonePayments	579800000	USD
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	3300000	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	12200000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1155000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	45858000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	USD
CY2022Q1	pbyi	Cash Cash Equivalents And Shortterm Investments Fair Value CashCashEquivalentsAndShorttermInvestmentsFairValue	45857000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	69849000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	USD
CY2021Q4	pbyi	Cash Cash Equivalents And Shortterm Investments Fair Value CashCashEquivalentsAndShorttermInvestmentsFairValue	69847000	USD
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Concentration of Risk: </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents, marketable securities, and accounts receivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at <em style="font: inherit;"> March 31, 2022</em> were approximately $67.0 million. The Company does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-<em style="font: inherit;">1/P</em>-<em style="font: inherit;">1</em> or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its accounts receivables, net and product revenues, net. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on the credit worthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product and limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company relies exclusively on <em style="font: inherit;">third</em> parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those <em style="font: inherit;">third</em> parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company has <em style="font: inherit;">no</em> experience in drug formulation or manufacturing and does <em style="font: inherit;">not</em> intend to establish its own manufacturing facilities. The Company lacks the resources and expertise to formulate or manufacture NERLYNX and other drug candidates. While the drug candidates were being developed by Pfizer, both the drug substance and drug product were manufactured by <em style="font: inherit;">third</em>-party contractors. The Company is using the same <em style="font: inherit;">third</em>-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX. If the Company is unable to continue its relationships with <em style="font: inherit;">one</em> or more of these <em style="font: inherit;">third</em>-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on <em style="font: inherit;">one</em> or more <em style="font: inherit;">third</em>-party contractors to manufacture the commercial supply of drugs.</p>
CY2022Q1	pbyi	Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits	67000000.0	USD
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4041000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4569000	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1607000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1385000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1629000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	7277000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	7109000	USD
CY2022Q1	pbyi	Trade Accounts Receivable Net Excluding License Revenue Receivable TradeAccountsReceivableNetExcludingLicenseRevenueReceivable	21901000	USD
CY2021Q4	pbyi	Trade Accounts Receivable Net Excluding License Revenue Receivable TradeAccountsReceivableNetExcludingLicenseRevenueReceivable	29646000	USD
CY2022Q1	pbyi	License Revenue Receivable LicenseRevenueReceivable	0	USD
CY2021Q4	pbyi	License Revenue Receivable LicenseRevenueReceivable	0	USD
CY2022Q1	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	5138000	USD
CY2021Q4	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	2880000	USD
CY2022Q1	pbyi	Average Incremental Borrowing Rate AverageIncrementalBorrowingRate	0.109	pure
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000.0	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	6000000.0	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8000000.0	USD
CY2022Q1	pbyi	Finitelived Intangible Asset Expected Amortization Year Eight FinitelivedIntangibleAssetExpectedAmortizationYearEight	2000000.0	USD
CY2022Q1	us-gaap	Accounts Receivable Gross AccountsReceivableGross	27039000	USD
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	32526000	USD
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2021Q4	pbyi	Prepaid Cro Services Noncurrent PrepaidCROServicesNoncurrent	166000	USD
CY2022Q1	pbyi	Prepaid Other Clinical Development Expense Noncurrent PrepaidOtherClinicalDevelopmentExpenseNoncurrent	312000	USD
CY2021Q4	pbyi	Prepaid Other Clinical Development Expense Noncurrent PrepaidOtherClinicalDevelopmentExpenseNoncurrent	577000	USD
CY2022Q1	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	247000	USD
CY2021Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	611000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	719000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1354000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	9435000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	10338000	USD
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1300000	USD
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	USD
CY2022Q1	pbyi	Prepaid Cro Services Current PrepaidCROServicesCurrent	269000	USD
CY2021Q4	pbyi	Prepaid Cro Services Current PrepaidCROServicesCurrent	340000	USD
CY2022Q1	pbyi	Prepaid Other Clinical Development Current PrepaidOtherClinicalDevelopmentCurrent	2714000	USD
CY2021Q4	pbyi	Prepaid Other Clinical Development Current PrepaidOtherClinicalDevelopmentCurrent	2933000	USD
CY2022Q1	us-gaap	Prepaid Insurance PrepaidInsurance	2423000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3178000	USD
CY2022Q1	pbyi	Prepaid Professional Fess Current PrepaidProfessionalFessCurrent	890000	USD
CY2021Q4	pbyi	Prepaid Professional Fess Current PrepaidProfessionalFessCurrent	398000	USD
CY2022Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2420000	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2135000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8716000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8984000	USD
CY2022Q1	pbyi	Prepaid Cro Services Noncurrent PrepaidCROServicesNoncurrent	160000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8572000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1447000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.109	pure
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4131000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5631000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5805000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5983000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1508000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	23058000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4348000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	18710000	USD
CY2022Q1	us-gaap	Sublease Income SubleaseIncome	100000	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	362000	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	495000	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	510000	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	525000	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	134000	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	2026000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8617000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6981000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6861000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1591000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1756000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	200000	USD
CY2022Q1	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	90000000	USD
CY2021Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	90000000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	25879000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23875000	USD
CY2022Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	64121000	USD
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	66125000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000.0	USD
CY2022Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P8Y
CY2022Q1	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	30030000	USD
CY2021Q4	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	57137000	USD
CY2022Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8477000	USD
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8829000	USD
CY2022Q1	pbyi	Accrued Development Costs AccruedDevelopmentCosts	1511000	USD
CY2021Q4	pbyi	Accrued Development Costs AccruedDevelopmentCosts	2663000	USD
CY2022Q1	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	10807000	USD
CY2021Q4	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	11406000	USD
CY2022Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1496000	USD
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5083000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4207000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3878000	USD
CY2022Q1	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	1607000	USD
CY2021Q4	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	911000	USD
CY2022Q1	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	665000	USD
CY2021Q4	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	672000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1787000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	674000	USD
CY2022Q1	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	813000	USD
CY2021Q4	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	690000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	437000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	632000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	61837000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	92575000	USD
CY2022Q1	pbyi	Accrued Legal Verdict Expense Noncurrent AccruedLegalVerdictExpenseNoncurrent	0	USD
CY2021Q4	pbyi	Accrued Legal Verdict Expense Noncurrent AccruedLegalVerdictExpenseNoncurrent	0	USD
CY2022Q1	pbyi	Accrued Clinical Research Organization Services Noncurrent AccruedClinicalResearchOrganizationServicesNoncurrent	719000	USD
CY2021Q4	pbyi	Accrued Clinical Research Organization Services Noncurrent AccruedClinicalResearchOrganizationServicesNoncurrent	878000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	37000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	37000	USD
CY2022Q1	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	756000	USD
CY2021Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	915000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	62593000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	93490000	USD
CY2021Q4	pbyi	Restructuring Percentage Of Reduction In Headcount RestructuringPercentageOfReductionInHeadcount	0.13	pure
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	102000000	USD
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4619000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	97381000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	33997000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	45329000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	22674000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	102000000	USD
CY2022Q1	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	791000	USD
CY2021Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	502000	USD
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4619000	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4908000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	200000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	500000	USD
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2011Q4	pbyi	Ordinary Shares Ownership Percentage OrdinarySharesOwnershipPercentage	0.20	pure
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3148000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5860000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.64
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.54
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	835297
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	7.76
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	482353
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.64
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	178552
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	8.43
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1139098
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.06
CY2022Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000	USD
CY2021Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	USD
CY2022Q1	pbyi	Milestone Payments Maximum Amount MilestonePaymentsMaximumAmount	187500000	USD
	pbyi	Percentage Of Unpaid Portion Of Milestone Payments Interest Rate PercentageOfUnpaidPortionOfMilestonePaymentsInterestRate	0.0625	pure
	pbyi	Milestone Payment MilestonePayment	1800000	USD

Files In Submission

Name	View Source	Status
0001437749-22-011142-index-headers.html	Edgar Link	pending
0001437749-22-011142-index.html	Edgar Link	pending
0001437749-22-011142.txt	Edgar Link	pending
0001437749-22-011142-xbrl.zip	Edgar Link	pending
ex_346524.htm	Edgar Link	pending
ex_346525.htm	Edgar Link	pending
ex_346526.htm	Edgar Link	pending
ex_346527.htm	Edgar Link	pending
ex_346528.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbyi-20220331.xsd	Edgar Link	pending
pbyi-20220331_cal.xml	Edgar Link	unprocessable
pbyi-20220331_def.xml	Edgar Link	unprocessable
pbyi-20220331_lab.xml	Edgar Link	unprocessable
pbyi-20220331_pre.xml	Edgar Link	unprocessable
pbyi20220331b_10q.htm	Edgar Link	pending
pbyi20220331b_10q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2022 Q1 Form 10-Q Financial Statement

#000143774922011142 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2022 Q1 Form 10-Q Financial Statement

#000143774922011142 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi